Loreev XR (lorazepam extended-release) coverage
Defines Cigna's coverage stance for Loreev XR (lorazepam extended-release capsules) for treatment of anxiety disorders and other uses for members under Cigna-administered health benefit plans.
No material clinical or coverage changes in this revision.
Coverage Criteria
Not covered (Not medically necessary)
Covered when ALL of the following are met
Policy states Loreev XR has no advantage in safety or efficacy over immediate‑release lorazepam, is primarily for convenience, and was approved via the 505(b)(2) pathway relying on immediate‑release data.
Loreev XR (lorazepam extended-release) is not covered for the treatment of anxiety disorders or for any other use. The product is considered not medically necessary for all indications.
Loreev XR provides a once-daily formulation of lorazepam but offers no advantage in safety or efficacy compared with immediate-release lorazepam. Because it requires that patients already be stable and compliant on evenly divided, three times daily immediate‑release lorazepam before conversion, its use is considered primarily for the convenience of the individual and therefore not medically necessary for any use.
Provider Actions and Prior Authorization
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.